title: Adventitia-dependent relaxations of canine basilar arteries transduced with recombinant eNOS gene.
abstract: We recently reported that expression of recombinant endothelial nitric oxide (NO) synthase (eNOS) gene in adventitial fibroblasts restores NO formation in canine cerebral arteries without endothelium in response to bradykinin ex vivo and in vivo. The present study was designed to further characterize the stimuli that can activate recombinant eNOS enzyme expressed in the adventitia of cerebral arteries. To stimulate recombinant eNOS, we used serum (0. 1-10%), substance P (10(-11)-3 x 10(-9) M), and ANG II (10(-7)-10(-5) M) because they increase intracellular calcium concentrations in fibroblasts. Endothelium-denuded segments of canine basilar arteries were incubated with an adenoviral vector encoding beta-galactosidase gene or eNOS gene for 30 min at 37 degrees C. After 24 h, vasomotor activity and cGMP formation in eNOS or beta-galactosidase arteries were examined by isometric force recording and by radioimmunoassay, respectively. In control arteries and beta-galactosidase gene-transduced arteries, serum caused concentration-dependent contractions, whereas in recombinant eNOS gene-transduced arteries, serum produced concentration-dependent relaxations. Substance P and ANG II had no effect on vascular tone in control and beta-galactosidase arteries but caused concentration-dependent relaxations as well as a significant increase in cGMP levels in eNOS arteries. These relaxations were blocked by the NOS inhibitor NG-nitro-L-arginine methyl ester. Chemical treatment or mechanical inactivation of adventitial function significantly attenuated substance P-induced relaxations and ANG II-induced relaxations. These findings demonstrate that serum, substance P, and ANG II cause adventitia-dependent relaxations in cerebral arteries expressing the recombinant eNOS gene. This mechanism of vasodilatation may have beneficial effects in the prevention and treatment of vascular disorders characterized by the diminished bioavailability of NO, such as cerebral vasospasm.
authors.affiliation: Department of Anesthesiology and Pharmacology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: M
authors.initials: M
authors.lastname: Tsutsui
authors.forename: H
authors.initials: H
authors.lastname: Onoue
authors.forename: Y
authors.initials: Y
authors.lastname: Iida
authors.forename: L
authors.initials: L
authors.lastname: Smith
authors.forename: T
authors.initials: T
authors.lastname: O'Brien
authors.forename: Z S
authors.initials: ZS
authors.lastname: Katusic
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001488:Basilar Artery / Q000187:drug effects / Q000502:physiology*; D001790:Blood Physiological Phenomena; D006152:Cyclic GMP / Q000378:metabolism; D004285:Dogs; D018014:Gene Transfer Techniques; D066298:In Vitro Techniques; D019001:Nitric Oxide Synthase / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III; D011994:Recombinant Proteins; D013373:Substance P / Q000494:pharmacology; D014664:Vasodilation / Q000502:physiology*
chemical_list: D011994:Recombinant Proteins; D000804:Angiotensin II; D013373:Substance P; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D006152:Cyclic GMP